Cargando…

Role of PET imaging for biochemical recurrence following primary treatment for prostate cancer

Prostate cancer is one of the most common cancers in men worldwide, and primary prostate cancer is typically treated with surgery, radiation, androgen deprivation, or a combination of these therapeutic modalities. Despite technical advances, approximately 30% of men will experience biochemical recur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galgano, Samuel J., Valentin, Roberto, McConathy, Jonathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178324/ https://www.ncbi.nlm.nih.gov/pubmed/30363475 http://dx.doi.org/10.21037/tau.2018.06.09

Ejemplares similares

Lymph node imaging in initial staging of prostate cancer: An overview and update
por: Zarzour, Jessica G, et al.
Publicado: (2017)

Image Quantification for TSPO PET with a Novel Image-Derived Input Function Method
por: Fang, Yu-Hua Dean, et al.
Publicado: (2022)

Imaging the L-Type Amino Acid Transporter-1 (LAT1) with Zr-89 ImmunoPET
por: Ikotun, Oluwatayo F., et al.
Publicado: (2013)

Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate Cancer
por: Galgano, Samuel J., et al.
Publicado: (2022)

Feasibility of Dose Escalating [(18)F]fluciclovine Positron Emission Tomography Positive Pelvic Lymph Nodes During Moderately Hypofractionated Radiation Therapy for High-Risk Prostate Cancer
por: McDonald, Andrew M., et al.
Publicado: (2019)

Advanced Imaging of Biochemical Recurrent Prostate Cancer With PET, MRI, and Radiomics
por: Shaikh, Faiq, et al.
Publicado: (2020)

The Potential Role of Nanotechnology in Therapeutic Approaches for Triple Negative Breast Cancer
por: Johnson, Rebecca, et al.
Publicado: (2013)

Racial Differences in Alzheimer’s Disease Specialist Encounters Are Associated with Usage of Molecular Imaging and Dementia Medications: An Enterprise-Wide Analysis Using i2b2
por: Murchison, Charles F., et al.
Publicado: (2021)

The Value of Multimodality PET/CT Imaging in Detecting Prostate Cancer Biochemical Recurrence
por: Jiang, Jie, et al.
Publicado: (2022)

Feasibility of MRI attenuation correction in cardiac FDG-PET
por: Lau, Jeffrey M, et al.
Publicado: (2013)

Hybrid imaging with [(68)Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer
por: Glemser, P. A., et al.
Publicado: (2022)

Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy
por: Lacy, John M., et al.
Publicado: (2016)

Role of molecular imaging in the detection of localized prostate cancer
por: Galgano, Samuel J., et al.
Publicado: (2022)

The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics
por: Cruz, Pedro M. R., et al.
Publicado: (2013)

Diagnostic Accuracy of (18)F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence
por: Sprute, Katharina, et al.
Publicado: (2021)

Ga-68-PSMA-11 PET/CT in Patients with Biochemical Recurrence of Prostate Cancer after Primary Treatment with Curative Intent—Impact of Delayed Imaging
por: Kunikowska, Jolanta, et al.
Publicado: (2022)

A Prospective Study on (18)F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
por: Rousseau, Etienne, et al.
Publicado: (2019)

HDL as a drug and nucleic acid delivery vehicle
por: Lacko, Andras G., et al.
Publicado: (2015)

PSMA PET-CT Imaging Predicts Treatment Progression in Men with Biochemically Recurrent Prostate Cancer—A Prospective Study of Men with 3 Year Follow Up
por: Ong, Sean, et al.
Publicado: (2022)

Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles
por: Sabnis, Nirupama, et al.
Publicado: (2012)

The value of (68)Ga-PSMA enhanced PET-CT and MR-PET in patients with biochemical recurrent prostate cancer
por: Rummeny, E, et al.
Publicado: (2015)

Initial Institutional Experience with 18F-Fluciclovine PET-CT in Biochemical Recurrence of Prostate Cancer
por: Farkas, Amy B., et al.
Publicado: (2021)

(18)F-PSMA-1007 PET in Biochemical Recurrent Prostate Cancer: An Updated Meta-Analysis
por: Ferrari, Matteo, et al.
Publicado: (2021)

Diagnostic accuracy of [(18)F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer
por: Mingels, Clemens, et al.
Publicado: (2022)

Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer
por: von Eyben, Rie, et al.
Publicado: (2023)

Management of Biochemical Recurrence after Primary Localized Therapy for Prostate Cancer
por: Darwish, Oussama M., et al.
Publicado: (2012)

Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0
por: Law, Ian, et al.
Publicado: (2018)

Imaging quality of an artificial intelligence denoising algorithm: validation in (68)Ga PSMA-11 PET for patients with biochemical recurrence of prostate cancer
por: Margail, Charles, et al.
Publicado: (2023)

Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer
por: Borno, Hala T., et al.
Publicado: (2020)

Diagnostic performance of (18)F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer
por: Rahbar, Kambiz, et al.
Publicado: (2018)

(18)F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review
por: Rais-Bahrami, Soroush, et al.
Publicado: (2021)

Evaluation of Predictors of Biochemical Recurrence in Prostate Cancer Patients, as Detected by (68)Ga-PSMA PET/CT
por: Christensen, Mads T., et al.
Publicado: (2022)

Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with (68)Ga-PSMA-11-PET
por: Ferraro, Daniela A., et al.
Publicado: (2020)

Evidence of neuroinflammation in fibromyalgia syndrome: a [(18)F]DPA-714 positron emission tomography study
por: Mueller, Christina, et al.
Publicado: (2023)

Diagnostic Role of (18)F-FECH-PET/CT Compared with Bone Scan in Evaluating the Prostate Cancer Patients Referring with Biochemical Recurrence
por: Takesh, Mustafa, et al.
Publicado: (2012)

Predicting biochemical recurrence of prostate cancer with artificial intelligence
por: Pinckaers, Hans, et al.
Publicado: (2022)

Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications
por: Welch, Brian T., et al.
Publicado: (2018)

Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology
por: Kasten, Benjamin B., et al.
Publicado: (2019)

One-year experience with (68)Ga-PSMA PET/CT: applications and results in biochemical recurrence of prostate cancer
por: Prado Júnior, Luciano Monteiro, et al.
Publicado: (2018)

Optimal MRI sequences for (68)Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer
por: Lake, Spencer T., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4qar7am7skkb277haleppv0u4o